Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Champions Oncology (CSBR) Stock Price & Analysis

143 Followers

CSBR Stock Chart & Stats

$4.78$0.03(0.63%)
At close: 4:00 PM EST
$4.75$5$5.25Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$4.64 - $4.81
52-Week Range
$4.59 - $8.31
Previous Close
$4.75
Volume
N/A
Average Volume (3M)
8,112
Market Cap
$66.11M
Enterprise Value
$81.67M
Total Cash (Recent Filing)
$4.36M
Total Debt (Recent Filing)
$10.97M
Price to Earnings (P/E)
―
Beta
0.16
Next Earnings
Dec 15, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Margin And EBITDA Improvement

The combination of revenue growth, sharply higher gross margin, and sustained adjusted EBITDA profitability indicates improving operating leverage in the core services business. If maintained, this progress can strengthen internal funding capacity and support more durable earnings improvement over the next several quarters.

Tumor Bank And Data Differentiation

A high-quality tumor bank and clinically annotated patient-derived data can differentiate Champions in oncology research services, where customers need credible translational evidence. This specialized asset base may support customer retention, pricing power, and expansion of service and data opportunities over time.

Growing Data Licensing Platform

The emergence of meaningful data licensing revenue broadens Champions’ business beyond fee-for-service studies and creates a potentially scalable monetization channel. A robust pipeline and growing customer base could improve revenue mix and increase the strategic value of the company’s proprietary oncology data.

Bears Say

Revenue And Profitability Volatility

The recent contraction in revenue and return to a net loss show that improved quarterly execution has not yet translated into consistent company-wide profitability. The history of swings between losses and profit reduces earnings visibility and makes sustained operating progress harder to establish.

Cash Burn And Elevated Leverage

Negative operating and free cash flow mean the business is currently consuming rather than generating cash, while higher leverage reduces financial flexibility. Persistent cash burn could constrain investment in growth initiatives and increase reliance on financing if operating performance weakens.

Lumpy Revenue And Corellia Uncertainty

Lumpy licensing contracts can make revenue and cash generation uneven, complicating planning and weakening near-term earnings visibility. Corellia’s uncertain funding or licensing outcome also leaves current investment commitments unresolved and makes any expected resource redeployment conditional.

Champions Oncology News

CSBR FAQ

What was Champions Oncology’s price range in the past 12 months?
Champions Oncology lowest stock price was $4.59 and its highest was $8.31 in the past 12 months.
What is Champions Oncology’s market cap?
Champions Oncology’s market cap is $66.11M.
When is Champions Oncology’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Champions Oncology’s earnings last quarter?
Champions Oncology released its earnings results on Sep 10, 2026. The company reported $0.05 earnings per share for the quarter.
Is Champions Oncology overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Champions Oncology pay dividends?
Champions Oncology does not currently pay dividends.
What is Champions Oncology’s EPS estimate?
Champions Oncology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Champions Oncology have?
Champions Oncology has 13,918,569 shares outstanding.
What happened to Champions Oncology’s price movement after its last earnings report?
Champions Oncology reported an EPS of $0.05 in its last earnings report. Following the earnings report the stock price went up 0.098%.
Which hedge fund is a major shareholder of Champions Oncology?
Hedge funds hold Champions Oncology shares: the largest hedge-fund position in Champions Oncology is 71,884,392 shares, and hedge funds increased their holdings by 5.9K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology